The Importance of Aspirin Use in Cancer

Year 2016, Volume: 18 Issue: 2, 73 - 76, 01.07.2016

Ebubekir Dirican

Abstract

In recent years, although crucial develeopment of diagnosis and curation for many cancers, it isa serious health problem has high mortality and morbidity worldwide. Therefore scientists havefocused on targeted therapy approaches lately. An inbitor or a drug, target spesific, may getsuccesful results inhibiting cell proliferation and cell growth in development of cancer. Lastdays, several important studies demonstrated that low dose aspirin utilization decreased insidinceand mortality of many cancers including colorectal, breast, gastric and lung cancer. In this reviewwe tried to summarize that aspirin utilization and ıts effects on cancer molecular mechanismsby current studies. Clarifying these mechanisms will provide an insight needed to developsignificant advancements for cancer therapy. Herewith it will be needed to determine aspirinusage profile of patients for each kind of cancer, getting either low or high aspirin dose forwhich cancer type and benefit risk ratio. Finally, survival of patients may be increased utilizinganti cancer effects of aspirin, a cheap, accesible and easily obtainable nonsteroidal drug and bythis way mortality rate of cancer may reduce in the future

Keywords

Aspirin, mortality, morbidity, targeted therapy, survival

KANSERDE ASPİRİN KULLANIMININ ÖNEMİ

Abstract

Son yıllarda kanserin tanı ve tedavisinde birçok önemli gelişme olmasına rağmen, dünya çapındahala mortalitesi ve morbiditesi yüksek ciddi bir sağlık sorunudur. Bu yüzden bilim insanları sonzamanlarda ‘hedefe yönelik tedavi’ şekillerinin üzerinde yoğunlaşmış durumdadırlar. Hedefeyönelik geliştirilecek bir inhibitör veya ilaç, kanserleşme sürecinde hücre proliferasyonu veyahücre büyümesini baskılayarak başarılı sonuçlar elde edilmesini sağlayacaktır. Son günlerdebirkaç önemli çalışmada düşük doz aspirin kullanımının kolorektal, meme, gastrik, akciğer veyadiğer kanserlerin insidansını ve mortalitesini düşürdüğü gösterilmiştir. Biz de bu derlemedeaspirin kullanımı ve kanserdeki etkilerinin moleküler mekanizmalarını yapılmış güncelçalışmalarla özetlemeye çalıştık. Bu mekanizmaların aydınlatılması kanser tedavisinde önemligelişmelerin ortaya çıkmasına ışık tutacaktır. Bu yüzden her bir kanser türünde hastaların aspirinkullanım profillerinin belirlenmesi gerekecek ve hangi kanser türünde düşük veya yüksek dozaspirin kullanılacağı ve risk-yarar durumları belirlenmiş olacaktır. Sonuç olarak ucuz, ulaşılabilirve kolay temin edilebilir bir non-steroidal ilaç (NSİ) olan aspirinin anti-kanser etkilerindenyararlanılarak kanser hastalarının sağkalımları arttırılabilecek ve gelecekte kanserden ölümriskleri düşürülebilecektir

Keywords

Aspirin, mortalite, morbidite, hedefe yönelik tedavi, sağkalım

References

• Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012;367(17):1596-606.
• Honn KV, Tang DG, Crissman JD. Platelets and cancer metastasis: a causal relationship? Cancer Metastasis Rev 1992;11(3-4):325-51.
• Brasky TM, Bonner MR, Moysich KB, et al. Non steroidal anti- inflammatory drug use (NSAID) and breast cancer risk in theWestern New York Exposures and Breast Cancer (WEB) Study. Cancer Causes Control 2010;9:1503-1512.
• Li X, Gao L, Cui Q, et al. Sulindac inhibits tumor cell invasion by suppressing NF-κB-mediated transcription of microRNAs. Oncogene 2012;31:4979-4986.
• Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. JNCI J Natl Cancer Inst 2009;101(4):256-66.
• Coyle C, Cafferty FH, Langley RE. Aspirin and Colorectal Cancer Prevention and Treatment: Is It for Everyone? Curr Colorectal Cancer Rep 2016;12:27-34.
• Bosetti C, Rosato V, Gallus S, et al. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol 2012;23(6):1403-15.
• Ruder EH, Laiyemo AO, Graubard BI, et al. Non-steroidal anti- inflammatory drugs and colorectal cancer risk in a large, prospective cohort. Am J Gastroenterol 2011;106(7):1340-50.
• Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012;379:1591-601.
• Nan H, Hutter CM, Lin Y, et al. Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants. JAMA 2015;313:1133-42.
• Zhong S, Chen L, Zhang X, et al. Aspirin use and risk of breast cancer: systematic review and meta-analysis of observational studies. 2015;24(11):1645-55. Biomarkers Prev
• Anderson WF, Chu KC, Chatterjee N, et al. Tumor variants by hormone receptor expression in white patients with nodenegative breast cancer from the surveillance, epidemiology, and end results database. J Clin Oncol 2001;19:18-27. 13. Howe LR. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res 2007;9:210.
• Maity G, De A, Das A, et al. Aspirin blocks growth of breast tumor cells and tumor-initiating cells and induces reprogramming factors of mesenchymal to epithelial transition. Lab Invest 2015;95(7):702-17.
• Skriver C, Dehlendorff C, Borre M, et al. Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk: a nationwide study. Cancer Causes Control 2016;27(9):1067-79.
• Barton MK. Daily aspirin may reduce mortality from prostate cancer with risk of high recurrence. CA Cancer J Clin 2015;65(2):83-4.
• Huang TB, Yan Y, Guo ZF, et al. Aspirin use and the risk of prostate cancer: a meta-analysis of 24 epidemiologic studies. Int Urol Nephrol 2014;46(9):1715-28.
• Cossack M, Ghaffary C, Watson P, et al. Aspirin use is associated with lower prostate cancer risk in male carriers of BRCA mutations. J Genet Couns 2014;23(2):187-91.
• Kashiwagi E, Shiota M, Yokomizo A, et al. Prostaglandin receptor EP3 mediates growth inhibitory effect of aspirin through androgen receptor and contributes to castration resistance in prostate cancer cells. Endocr Relat Cancer 2013;20(3):431-34.
• Li XF, Xu BZ, Wang SZ. Aspirin inhibits the proliferation and migration of gastric cancer cells in p53-knockout mice. Oncol Lett. 2016;12(5):3183-3186.
• Kim YI, Kim SY, Kim JH, et al. Long-Term Low-Dose Aspirin Use Reduces Gastric Cancer Incidence: A Nationwide Cohort Study. Cancer Res Treat 2016;48(2):798-805.
• Yang L, Zhu H, Liu D, et al. Aspirin suppresses growth of human gastric carcinoma cell by inhibiting survivin expression. J Biomed Res 2011;25(4):246-53.
• Tian W, Zhao Y, Liu S, et al. Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. Eur J Cancer Prev 2010;19(4):288-98.
• Tahara T, Shibata T, Nakamura M, et al. Chronic aspirin use suppresses CDH1 methylation in human gastric mucosa. Dig Dis Sci 2010;55(1):54-9.
• Oshima T, Miwa H, Joh T. Aspirin induces gastric epithelial barrier dysfunction by activating p38 MAPK via claudin-7. Am J Physiol Cell Physiol 2008;295(3):C800-6.
• Leung AM, Redlak MJ, Miller TA. Aspirin-induced mucosal cell death in human gastric cells: role of a caspase- independent mechanism. Dig Dis Sci 2009;54(1):28-35.
• Redlak MJ, Power JJ, Miller TA. Prevention of deoxycholate- induced gastric apoptosis by aspirin: roles of NF-kappaB and PKC signaling. J Surg Res 2008;145(1):66-73.
• Khan P, Manna A, Saha S, et al. Aspirin inhibits epithelial-to- mesenchymal transition and migration of oncogenic K-ras-expressing non-small cell lung carcinoma cells by down-regulating E-cadherin repressor Slug. BMC Cancer. 2016;16:39.
• Mc Menamin ÚC, Cardwell CR, et al. Low-dose aspirin and survival from lung cancer: a population-based cohort study. BMC Cancer 2015;15:911.
• Hochmuth F, Jochem M, Schlattmann P. Meta-analysis of aspirin use and risk of lung cancer shows notable results. Eur J Cancer Prev 2016;25(4):259-68.
• O'Brien AJ, Villani LA, Broadfield LA, et al. Salicylate activates AMPK and synergizes with metformin to reduce the survival of prostate and lung cancer cells ex vivo through inhibition of de novo lipogenesis. Biochem J 2015;469(2):177-87.
• Jiang HY, Huang TB, Xu L, et al. Aspirin use and lung cancer risk: a possible relationship? Evidence from an updated meta- analysis. PLoS One 2015 Apr 7;10(4):e0122962
• Ramon S, Woeller CF, Phipps RP. The influence of Cox-2 and bioactive lipids on hematological cancers. Curr Angiogenes 2013;2(2):135-142.
• Bellosillo B, Pique M, Barragan M, et al. Aspirin and salicylate induce apoptosis and activation of caspases in B- cell chronic lymphocytic leukemia cells. Blood 1998;92(4):1406-614.
• Chang ET, Zheng T, Weir EG, et al. Aspirin and the risk of Hodgkin's lymphoma in a population-based case-control study. J Natl Cancer Inst 2004;96(4):305-15.
• Holly EA, Lele C, Bracci PM, et al. Case-control study of non- Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay Area, California. Am J Epidemiol 1999;150(4):375-89.